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background
 
Osteoporotic structural damage and bone fragility result from reduced bone formation
and increased bone resorption. In a phase 2 clinical trial, strontium ranelate, an orally
active drug that dissociates bone remodeling by increasing bone formation and decreas-
ing bone resorption, has been shown to reduce the risk of vertebral fractures and to in-
crease bone mineral density.
 
methods
 
To evaluate the efficacy of strontium ranelate in preventing vertebral fractures in a phase
3 trial, we randomly assigned 1649 postmenopausal women with osteoporosis (low
bone mineral density) and at least one vertebral fracture to receive 2 g of oral strontium
ranelate per day or placebo for three years. We gave calcium and vitamin D supplements
to both groups before and during the study. Vertebral radiographs were obtained annu-
ally, and measurements of bone mineral density were performed every six months.
 
results
 
New vertebral fractures occurred in fewer patients in the strontium ranelate group than
in the placebo group, with a risk reduction of 49 percent in the first year of treatment
and 41 percent during the three-year study period (relative risk, 0.59; 95 percent confi-
dence interval, 0.48 to 0.73). Strontium ranelate increased bone mineral density at month
36 by 14.4 percent at the lumbar spine and 8.3 percent at the femoral neck (P<0.001 for
both comparisons). There were no significant differences between the groups in the
incidence of serious adverse events.
 
conclusions
 
Treatment of postmenopausal osteoporosis with strontium ranelate leads to early and
sustained reductions in the risk of vertebral fractures.
abstract
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ertebral fractures, a serious con-
 
sequence of osteoporosis, lead to acute and
chronic back pain, spinal deformity, and
a reduction in survival equivalent to that caused by
hip fractures.
 
1
 
 The health care burden in financial
terms is substantial.
 
2
 
 Vertebral deformities predict
further vertebral fracture, even within one year, and
also predict nonvertebral fractures.
 
1,3,4
 
The bone fragility that characterizes osteoporo-
sis after menopause results both from an imbalance
in bone remodeling at the cellular level, which caus-
es bone resorption to exceed bone formation, and
from an increase in the rate of remodeling at the
tissue level.
 
5
 
 Antiresorptive therapies reduce the rate
of bone remodeling and lower the fracture rate by
30 to 50 percent. Antiresorptive agents, however, do
not increase bone tissue mass. Instead, the increase
in bone mineral density observed in clinical trials
of antiresorptive drugs is the result of a more com-
plete secondary mineralization of the existing (but
reduced) bone tissue mass.
 
6-10
 
 Restoration of bone
tissue mass and bone structure is not achieved with
antiresorptive drugs and requires the use of anabol-
ic agents.
 
11,12
 
Strontium ranelate is a new orally active agent
consisting of two atoms of stable strontium and an
organic moiety (ranelic acid). It stimulates the for-
mation of new bone tissue and decreases bone re-
sorption, as has been shown in vitro and in experi-
ments in animals.
 
13-16
 
 Strontium ranelate prevents
bone loss in ovariectomized rats, increases bone
mass in osteopenic animals, and increases bone
strength in normal animals.
 
13,17,18
 
 To date, no del-
eterious effects on the primary or secondary miner-
alization of bone in laboratory animals
 
18,19 
 
or
humans
 
20
 
 have been reported. Results from a two-
year placebo-controlled, phase 2, dose–response
study involving 353 postmenopausal women with
osteoporosis suggested that ingestion of 2 g a day
of oral strontium ranelate reduced the incidence of
vertebral fractures during the second year of treat-
ment and simultaneously increased bone mineral
density.
 
20
 
 In order to confirm these results, we de-
signed the Spinal Osteoporosis Therapeutic Inter-
vention study to test the safety of strontium rane-
late and its efficacy against vertebral fracture when
given orally at a dose of 2 g per day for three years in
postmenopausal women with osteoporosis and a
history of vertebral fracture.
 
study subjects
 
We recruited postmenopausal women from Novem-
ber 1996 through July 1998 at 72 centers in 11 Euro-
pean countries and Australia for this prospective,
randomized, double-blind, placebo-controlled trial.
Women were eligible for the study if they were at
least 50 years old, had been postmenopausal for at
least five years, had had at least one fracture con-
firmed by spinal radiography (after minimal trau-
ma), and had a lumbar-spine bone mineral density
of 0.840 g per square centimeter or less (measured
with Hologic instruments). Women were ineligible
if they had severe diseases or conditions that could
interfere with bone metabolism or if they used anti-
osteoporotic treatments (fluoride salts and bis-
phosphonates taken for more than 14 days within
the previous 12 months, or estrogen, calcitonin, or
calcitriol taken for more than 1 month in the previ-
ous 6 months). All participants provided written in-
formed consent before enrollment in the study; the
study was approved by the institutional review board
at each center.
 
treatment protocol and follow-up
 
Throughout the study, subjects received daily cal-
cium supplements at lunchtime (up to 1000 mg of
elemental calcium, depending on their dietary cal-
cium intake), to maintain a daily calcium intake
above 1500 mg, and vitamin D (400 to 800 IU, de-
pending on the base-line serum concentration of
25-hydroxyvitamin D). After a run-in period of 2 to
24 weeks, depending on the severity of the defi-
ciency of calcium and vitamin D, the subjects were
randomly assigned to receive 2 g a day of strontium
ranelate (two packets a day of a powder that they
mixed with water) or placebo powder for 3 years.
Subjects were instructed to take the study drug once
daily, at bedtime, or twice daily (one packet 30 min-
utes before breakfast, and one at bedtime). Most
subjects (87 percent) chose the once-daily regimen.
Three lateral radiographs of the spine (thoracic
and lumbar radiographs and an image of the thora-
columbar junction) were obtained at base line and
annually, according to standardized procedures, and
if there were indications of symptomatic vertebral
fracture (acute back pain, a decrease in body height
of at least 1 cm, or both). At base line, anteroposte-
v methods
The New England Journal of Medicine 
Downloaded from nejm.org at UQ Library on April 4, 2017. For personal use only. No other uses without permission. 
 Copyright © 2004 Massachusetts Medical Society. All rights reserved. 
 n engl j med 
 
350;5
 
www.nejm.org january 
 
29, 2004
 
strontium ranelate and vertebral fracture in postmenopausal osteoporosis
 
461
 
rior radiographs of the spine were also obtained.
All radiographs were assessed at a central facility;
radiologists were told the time sequence of each ra-
diograph but were unaware of the treatment as-
signment.
Two methods of assessing vertebral fracture
were used. First, a semiquantitative visual assess-
ment of each vertebra, from T4 to L4, was performed
by the same reader throughout the study. The semi-
quantitative grading scale was as follows: grade 0,
normal; grade 1, a decrease in the height of any ver-
tebra of 20 to 25 percent; grade 2, a decrease of 25
to 40 percent; and grade 3, a decrease of 40 percent
or more.
 
21,22
 
 For primary analysis, a new fracture
was defined by a change in the score of a vertebra
from grade 0 at base line to a subsequent grade of
1 or more. Second, quantitative assessment was also
performed: anterior, middle, and posterior verte-
bral heights were measured for each vertebra, from
T4 to L4. A new fracture was defined by a decrease
in height of at least 15 percent (or 3 mm) on a ver-
tebra graded 0 at base line and with a grade on the
semiquantitative scale of 1, 2, or 3.
 
23
 
Nonvertebral fractures were confirmed by a ra-
diologic evaluation or by a report from a hospital-
ization. (The study did not have sufficient power for
adequate statistical comparison of the two groups.)
Skull, face, finger, toe, and coccygeal fractures were
not considered to be osteoporotic fractures. Stand-
ing height was measured at base line and every six
months with a Harpenden stadiometer, according
to a standardized procedure.
Bone mineral density at the lumbar spine and
proximal femur was measured by dual-energy x-ray
absorptiometry at base line and at six-month inter-
vals (Hologic). All the scans were analyzed centrally.
A quality-control program was conducted through-
out the study.
 
24
 
 Lumbar-spine bone mineral densi-
ty, adjusted for the strontium content of the bone,
was calculated at month 36 according to the fol-
lowing formula
 
20
 
: adjustment factor = 1÷[1+(esti-
mated bone strontium content ¬ 0.61)], with bone
strontium content defined as the value measured in
bone-biopsy samples obtained in some subjects at
month 36.
Blood and urine samples were collected at base
line, three months, and six months, and then ev-
ery six months; the samples were stored at ¡80°C
and analyzed centrally. Biochemical tests were per-
formed by Bio Analytical Research Corporation
(BARC) according to standard methods. Serum con-
centrations of bone-specific alkaline phosphatase
(a marker of bone formation) were measured with
an immunoradiometric assay (Tandem-R Ostase,
Hybritech), serum concentrations of C-telopep-
tide cross-links (a marker of bone resorption) with
an enzyme-linked immunosorbent assay (Serum
CrossLaps, Osteometer Biotech), parathyroid hor-
mone with an immunoradiometric assay (N-tact,
DiaSorin), 25-hydroxyvitamin D with a radioimmu-
noassay (DiaSorin), and calcitonin with an immu-
noradiometric assay (Biosource). Also measured
was 1,25-dihydroxyvitamin D, by means of a radi-
 
Figure 1. Study Populations.
Randomized sample, 1649 patients
Strontium ranelate, 828
Placebo, 821
Safety sample, 1640 patients
Strontium ranelate, 826
Placebo, 814
9 Excluded: no treatment received
198 Excluded: no radiograph  
after base line
Analysis at 1 yr, 1385 patients
Strontium ranelate, 686
Placebo, 699
Completed follow-up at 3 yr, 1260 patients
Strontium ranelate, 628
Placebo, 632
Full analyzed sample (intention-to-
treat population), 1442 patients
Strontium ranelate, 719
Placebo, 723
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oreceptor assay (DiaSorin). The strontium con-
tent of serum and bone was measured with induc-
tively coupled plasma-emission spectrophotometry
(BARC), and the results were released only after the
randomization code had been broken.
Biopsies of transiliac bone were carried out after
tetracycline double labeling in 20 consenting pa-
tients to assess bone strontium content and safety-
related histomorphometric variables.
 
statistical analysis
 
The main efficacy analysis was performed on an in-
tention-to-treat basis and included patients who
underwent randomization, who had taken at least
one packet of treatment, and for whom at least one
spinal radiograph was obtained after base line. Kap-
lan–Meier product-limit estimates of the incidence
of new vertebral fractures were calculated at the time
each year when radiography was performed. An un-
adjusted Cox model served as the main statistical
analysis for the comparison of groups and the esti-
mation of relative risks and 95 percent confidence
intervals.
Two-sided Student’s t-tests were used to com-
pare percent changes from base line in independent
samples, the Pearson chi-square test was used to
compare the numbers of patients with at least two
new vertebral fractures and the numbers of patients
with a specific adverse event, and 95 percent confi-
dence intervals were determined for the differences
between the groups with respect to mean changes
in serum calcium, phosphorus, and parathyroid hor-
mone levels. For percent changes from the base-line
value in bone mineral density at each subsequent
visit, a step-down hierarchical procedure was per-
formed on the basis of the increasing treatment ef-
fect over time. The mean values in the two groups
at each visit were compared with the use of one-sid-
ed Student’s t-tests with a type I error rate of 2.5 per-
cent. The P values presented correspond to a two-
sided test at the 5 percent threshold. (One-sided
P values were doubled.)
The data and assessments collected in this study
were held by Servier, and statistical analyses were
performed by Servier. Data concerning bone min-
eral density, biochemical markers and other bio-
chemical variables, and the evaluation of spinal ra-
diographs were collected centrally by independent
investigators and then transferred to Servier for sta-
tistical analysis. The authors had access to all the
data and take responsibility for the veracity of the
analyses.
This study was coordinated and organized un-
der the control of an independent advisory com-
mittee, whose members were not directly involved
in the study, and the international coordinator (Dr.
Meunier), who monitored the scientific quality of
the studies, patient compliance and adherence to
the protocol, results, and conclusions. A steering
committee planned the study, its conduct, and the
statistical analysis, and it oversaw any scientific or
technical issues. The members of an adverse-events
committee were independent of the sponsor and of
other committees.
 
study subjects
 
Of 1649 women who underwent randomization,
87.4 percent (1442 women) made up the popula-
tion for the intention-to-treat analysis (Fig. 1). The
base-line characteristics of the two groups were
similar both in the intention-to-treat population
(Table 1) and among all patients randomly assigned
to treatment groups (data not shown). In the inten-
tion-to-treat population, 87.4 percent of the place-
results
 
* Plus–minus values are means ±SD. There were no significant differences be-
tween the groups.
† The body-mass index is the weight in kilograms divided by the square of the 
height in meters.
 
Table 1. Base-Line Characteristics of the 1442 Patients in the Intention-to-Treat 
Population.*
Characteristic
Placebo
(N=723)
Strontium
Ranelate
(N=719)
 
Age (yr) 69.2±7.3 69.4±7.2
Yr since menopause 21.6±8.7 22.1±8.8
Body-mass index† 26.2±4.1 26.1±4.1
Cigarette smoking (%) 11.3 12.4
Previous nonvertebral fracture (%) 32.0 33.7
No. of previous vertebral fractures 2.20±2.18 2.16±2.01
Bone mineral density at the lumbar spine
Mean (g/cm
 
2
 
)
T score
0.720±0.118
¡3.6±1.2
0.731±0.125
¡3.5±1.3
Bone mineral density at the femoral neck
Mean (g/cm
 
2
 
)
T score
0.591±0.093
¡2.8±0.8
0.591±0.086
¡2.8±0.8
Bone mineral density of the total hip
Mean (g/cm
 
2
 
)
T score
0.6811±0.113
¡2.4±1.1
0.685±0.109
¡2.4±1.1
Serum bone-specific alkaline phosphatase 
(ng/ml)
12.8±4.9 12.3±4.5
Serum C-telopeptide cross-links (pmol/liter) 4181±2034 4092±2401
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bo group and 87.3 percent of the strontium ranelate
group completed three years of follow-up.
 
vertebral fractures, body height, 
and nonvertebral fractures
 
At the end of the first year of treatment, there was a
49 percent lower risk of a new vertebral fracture in
the strontium ranelate group than in the placebo
group (incidence, 6.4 percent vs. 12.2 percent; rela-
tive risk, 0.51; 95 percent confidence interval, 0.36
to 0.74; P<0.001), and a 52 percent lower risk of
symptomatic fracture (3.1 percent vs. 6.4 percent;
relative risk, 0.48; 95 percent confidence interval,
0.29 to 0.80; P=0.003). Over the entire three-year
study period, the strontium ranelate group had a 41
percent lower risk of a new vertebral fracture than
the placebo group (20.9 percent vs. 32.8 percent;
relative risk, 0.59; 95 percent confidence interval,
0.48 to 0.73; P<0.001) (Fig. 2). On the basis of these
data, 9 patients would need to be treated for three
years with strontium ranelate in order to prevent
1 patient from having a vertebral fracture (95 per-
cent confidence interval, 6 to 14).
Quantitative assessment confirmed by the semi-
quantitative evaluation of vertebral fractures showed
that 17.7 percent of patients receiving strontium
ranelate for three years and 28.4 percent of patients
receiving placebo had one new vertebral fracture
that met the study criteria (relative risk in the stron-
tium ranelate group, 0.58; 95 percent confidence
interval, 0.46 to 0.73; P<0.001). The proportion of
patients with more than one new vertebral fracture
over the three-year period was 6.4 percent in the
strontium ranelate group and 9.8 percent in the pla-
cebo group (relative risk, 0.64; 95 percent confi-
dence interval, 0.44 to 0.93; P=0.02). Symptomatic
vertebral fractures were detected in 192 patients
(11.3 percent of the strontium ranelate group and
17.4 percent of the placebo group), corresponding
to a 38 percent lower risk over a period of three years
in the strontium ranelate group than in the control
group (relative risk, 0.62; 95 percent confidence in-
terval, 0.47 to 0.83; P<0.001).
Over the three-year treatment period, fewer pa-
tients had height loss of at least 1 cm in the stron-
tium ranelate group (30.1 percent) than in the pla-
cebo group (37.5 percent, P=0.003). Back pain was
reported by 17.7 percent of the women in the stron-
tium ranelate group and by 21.3 percent in the pla-
cebo group (P=0.07). Nonvertebral fractures oc-
curred in 234 women (112 in the strontium ranelate
group and 122 in the placebo group) over the study
period (relative risk, 0.90; 95 percent confidence
interval, 0.69 to 1.17).
 
bone mineral density, serum strontium 
levels, and markers of bone turnover
 
Bone mineral density was similar at base line in the
two groups and increased continuously at the spine,
femoral neck, and total hip in the strontium rane-
late group over the three-year period, with no trend
toward a plateau (Fig. 3). Over a period of three
years, bone mineral density in the strontium rane-
late group had increased from base line by 12.7 per-
cent at the lumbar spine, 7.2 percent at the femoral
neck, and 8.6 percent at the total hip (P<0.001 for
all three comparisons with base-line values), corre-
sponding to differences between the placebo and
the treatment groups at three years of 14.4 percent,
8.3 percent, and 9.8 percent, respectively. At three
years, the bone mineral density at the lumbar spine,
adjusted for the strontium content, showed an in-
crease over the base-line value of 6.8 percent in the
 
Figure 2. Proportion of Patients in the Intention-to-Treat 
Population Who Had One or More New Vertebral Frac-
tures, Assessed According to the Semiquantitative 
Method.
 
Analysis at month 12 was restricted to patients with as-
sessable radiographs at base line and at month 12 (686 
patients in the strontium ranelate group and 699 in the 
placebo group). The relative risk of fracture in the treat-
ment group at 12 months was 0.51 (95 percent confidence 
interval, 0.36 to 0.75; P<0.001). Analysis for the three-year 
period was restricted to patients with assessable radio-
graphs at base line and after base line (719 patients in 
the strontium ranelate group and 723 in the placebo 
group). The relative risk of fracture over 36 months 
was 0.59 (95 percent confidence interval, 0.48 to 0.73; 
P<0.001).
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strontium ranelate group and a decrease of 1.3 per-
cent in the placebo group (P<0.001); these changes
correspond to a treatment-related increase of 8.1
percent.
At base line, the median serum strontium con-
centration was 0.3 µmol per liter in both groups. At
three months, the median serum strontium con-
centration in the treated group had risen to 117.9
µmol per liter and then reached a plateau. At the
third month of therapy, the serum concentration of
bone-specific alkaline phosphatase was higher in
the strontium ranelate group than in the placebo
group (a treatment-related increase of 8.1 percent,
P<0.001), and this difference persisted at each eval-
uation during the three years (Fig. 4A and 4C). The
concentration of serum C-telopeptide cross-links
was lower in the strontium ranelate group than in
the placebo group at month 3 (a treatment-related
difference of 12.2 percent, P<0.001) and at each sub-
sequent evaluation during the three years (P<0.001)
(Fig. 4B and 4C).
 
histomorphometric features of bone
 
Bone biopsies were performed at 24, 36, or 48
months in 20 consenting patients, resulting in 14
samples that could be assessed. All biopsy speci-
mens consisted of lamellar bone. None of the biop-
sies showed evidence of osteomalacia or any sign of
a primary mineralization defect. As compared with
the placebo group, the strontium ranelate group had
no increase in osteoid thickness (P=0.64) or in the
mineralization lag time (P=0.76) and no decrease
in the mineral apposition rate (P=0.93).
 
adverse events and metabolic results
 
During the three years of the study, the rate of com-
pliance with therapy was 83 percent in the stron-
tium ranelate group and 85 percent in the placebo
group. The rates of adverse events, serious adverse
events, and withdrawal due to adverse events were
similar in the two groups. Diarrhea was the most
frequent gastrointestinal adverse event (occurring
in 6.1 percent of the strontium ranelate group and
3.6 percent of the placebo group, P=0.02). How-
ever, this effect disappeared after the first three
months. There was a lower incidence of gastritis,
as diagnosed clinically by the investigators, in the
strontium ranelate group than in the placebo group
(3.6 percent vs. 5.5 percent, P=0.07). Serum calci-
um concentrations were lower and serum phos-
phate concentrations higher in the strontium rane-
late group than in the control group at month 3, with
a plateau thereafter (95 percent confidence interval
for the difference between the groups, ¡0.32 to ¡0.20
mg per deciliter [¡0.08 to ¡0.05 mmol per liter] for
calcium and 0.25 to 0.37 mg per deciliter [0.08 to
0.12 mmol per liter] for phosphorus). There was a
slight reduction in serum parathyroid hormone
from the level at month 6 in both groups (decrease
 
Figure 3. Effects of Strontium Ranelate on Bone Mineral Density in All Pa-
tients Receiving 2 g a Day of Oral Strontium Ranelate.
 
P<0.001 for all comparisons, with the use of a step-down hierarchical procedure.
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Figure 4. Strontium Ranelate–Induced Changes in Serum Biochemical Markers of Bone Metabolism.
 
Panel A shows absolute changes from base-line values in bone-specific alkaline phosphatase, Panel B shows absolute 
changes from base-line values in C-telopeptide cross-links, and Panel C shows differences over time in biochemical 
markers between the two groups. Data shown are mean (±SE) values in the strontium ranelate group minus mean val-
ues in the placebo group. Comparisons were performed with analyses of covariance in which base-line values were used 
as covariates.
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from base-line to six-month values, ¡3.4
 
±
 
10.7 pg
per milliliter in the strontium ranelate group and
¡1.3
 
±
 
15.8 pg per milliliter in the placebo group).
No changes were observed for serum 25-hydroxyvi-
tamin D, 1,25-dihydroxyvitamin D, or calcitonin.
Serum creatine kinase concentrations in the
skeletal muscle increased in some patients; with a
high concentration defined as a value that was at
least twice the upper limit of the normal range (145
IU per liter), high levels were detected in 3.4 per-
cent of patients in the strontium ranelate group at
least once during the study and in 1.8 percent of
patients in the placebo group. No increase in mus-
cular symptoms or other biologic abnormalities
were observed. Most of the increases in creatine
phosphokinase were transient, and in more than
88 percent of the patients who had high concentra-
tions, the values returned to the normal range dur-
ing treatment.
Prevention of fractures is the primary aim of anti-
osteoporotic treatment. In the present study, stron-
tium ranelate ingested daily reduced the risk of new
vertebral fractures by 49 percent at one year and by
41 percent over a three-year period among post-
menopausal women with osteoporosis. Although
data from direct comparisons with other antios-
teoporotic treatments are lacking, the reduction in
the risk of vertebral fracture seems similar to the
reduction reported with alendronate (47 percent),
 
6
 
5 mg of risedronate (49 percent),
 
7
 
 60 mg of ralox-
ifene (30 percent),
 
8
 
 and parathyroid hormone (65
percent after 21 months of treatment).
 
12
 
 The meth-
ods of assessing vertebral fractures, involving both
semiquantitative and morphometric evaluations,
were similar to the methods used in these other re-
ports.
 
6-8,12
 
 Strontium ranelate also reduced the risk
of multiple vertebral fractures and the risk of symp-
tomatic fractures. In this group of women, who had
established osteoporosis and a history of fractures,
the number needed to treat to prevent one fracture
was nine.
Most antiresorptive agents prevent bone destruc-
tion by reducing the rate of bone remodeling, as
reflected by a decrease in both markers of bone re-
sorption (more than 50 percent with bisphospho-
nates and about 30 percent with raloxifene) and
markers of bone formation (about 50 percent with
bisphosphonates and 20 percent with raloxifene).
 
25
 
Treatment with parathyroid hormone increases both
bone formation and bone resorption.
 
26
 
 When para-
thyroid hormone and alendronate are combined,
there is, unexpectedly, no potentiation of their ef-
fects on biochemical bone markers.
 
27
 
 The mecha-
nism of action of strontium ranelate is probably dif-
ferent from those of these drugs. Each time the
patients were evaluated during our study, bone for-
mation had increased in the group assigned to stron-
tium ranelate, on the basis of serum concentrations
of bone-specific alkaline phosphatase, and bone re-
sorption had decreased, on the basis of serum con-
centrations of C-telopeptide cross-links, as com-
pared with the values in the placebo group. The
changes in biochemical markers of bone resorption
and formation were most pronounced during the
first six months; the dissociation between the bone
markers was evident throughout the study. The
mechanisms for the apparent dissociation between
reduced bone resorption and increased bone forma-
tion are not yet understood, but they probably dif-
fer from the mechanisms of current treatments.
 
6-9
 
 
Any metal with an atomic number higher than
that of calcium can be expected to influence bone
mineral density.
 
28
 
 In experiments, strontium in
bone correlated with strontium in plasma.
 
29
 
 In this
study, strontium ranelate increased bone mineral
density at three years by 14.4 percent at the lumbar
spine, by 8.3 percent at the femoral neck, and by
9.8 percent at the total hip, and bone strength is
directly proportional to bone mineral density. Al-
though data from directly comparable trials are not
available, the treatment effect after adjustment for
the strontium content of bone was an 8.1 percent
increase in bone mineral density at the lumbar spine
at 3 years, which compares favorably with a 9 per-
cent increase with parathyroid hormone (20 µg) at
21 months and with the increases with other drugs
(5.9 percent with risedronate, 6.2 percent with alen-
dronate, and 2.6 percent with raloxifene). Moreover,
this increase is consistent with the results of pre-
vious phase 2 studies involving strontium rane-
late.
 
20,30
 
 In summary, strontium ranelate given oral-
ly at a dose of 2 g daily appears to reduce the risk
of vertebral fractures rapidly, effectively, and safely
among postmenopausal women with osteoporosis.
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